The University of Chicago
Hyde Park, Illinois, 60637, United States
Location status: Recruiting
Location contact
John Alverdy, MD FACS FSIS
CONTACT
John Alverdy, MD FACS FSIS
PRINCIPAL_INVESTIGATOR
Leila Yazdanbakhsh, MD FACS FSIS
CONTACT
NCT Number: NCT06822465
Despite powerful antibiotics, 50% of the intestinal tracts of critically ill surgical patients are colonized by Pseudomonas aeruginosa, whose mere presence in this site increases mortality fourfold by mechanisms that remain unknown. Many patients who survive the initial surgical trauma still succumb to multi-organ failure and septicemia secondary to an invasive nosocomial infection. The sequelae of shock, hypoxia, and parental nutrition result in injury to the intestinal mucosa, changes in gut permeability, and failure of intestinal defense mechanisms. These conditions put patients at risk for infection and multiple organ failure secondary to the translocation of enteric bacteria, initiating a systemic release of inflammatory mediators-a process that has been termed gut-derived sepsis.
Intestinal P. aeruginosa senses host factors released during stress and responds by activating its virulence gene machinery. As such, the presence of a highly activating intestinal milieu serves to induce virulence in strains of P. aeruginosa and this correlates to the severity of a patient's illness. While the host-pathogen interaction is a dynamic process, the study expects that as a patient's illness worsens or resolves over time, the "virulence-activating" properties of their intestinal milieu will change accordingly. This study will conduct a prospective observational trial in a population of critically ill patients at the Universtiy of Chicago Medical Center. This trial will entail collecting and screening stool samples obtained from critically ill patients for their virulence inducing capabilities on laboratory strains of P. aeruginosa using in vitro and in vivo assays. The study also plans to isolate strains of intestinal P. aeruginosa from stool samples to determine the prevalence of intestinal P. aeruginosa in a population of critically ill patients.
Interested in participating?
Request Info18 year–85 year
All sexes
Observational
Hyde Park, Illinois, 60637, United States
Location status: Recruiting
John Alverdy, MD FACS FSIS
CONTACT
John Alverdy, MD FACS FSIS
PRINCIPAL_INVESTIGATOR
Leila Yazdanbakhsh, MD FACS FSIS
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This trial will entail collecting and screening stool samples obtained from critically ill patients for their virulence inducing capabilities on laboratory strains of P. aeruginosa using in vitro and in vivo assays. The investigators also plan to isolate strains of intestinal P. aeruginosa from stool samples to determine the prevalence of intestinal P. aeruginosa in a population of critically ill patients.
Time frame: Through study completion, an average of 3 years
Time frame: Through study completion, an average of 3 years
Time frame: Through study completion, an average of 3 years
Contact information is provided by the study sponsor or research team.
John Alverdy, MD FACS FSIS
CONTACT
Leila Yazdanbakhsh, MSCI
CONTACT
University of Chicago
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06738771
Antibacterial Agents, Bacterial Infections
Amiens, France
View Trial DetailsNCT04335383
Bacterial Infections, Bacterial Infections and Mycoses
Grenoble, France
View Trial DetailsNCT07056881
Bacterial Infections, Bacterial Infections and Mycoses
Saint-Denis, France
View Trial DetailsNCT06016088
Bacterial Infections, Bacterial Infections and Mycoses
Tucson, Arizona, United States
View Trial Details